tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Janux Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Brad Canino initiated coverage of Janux Therapeutics (JANX) with a Buy rating and $72 price target The firm believes the company can create significant shareholder value given its “best-in-category” JANX007 prostate-specific antigen responses in metastatic castration-resistant prostate cancer. The analyst views Janux as an attractive pure-play investment for T cell engagers in solid tumors.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1